1. Anti-infection
    Metabolic Enzyme/Protease
  2. HIV
    HIV Protease

Atazanavir sulfate (Synonyms: BMS-232632 sulfate)

Cat. No.: HY-17367A Purity: 99.64%
Handling Instructions

Atazanavir sulfate is a sulfate salt form of atazanavir that is an highly potent HIV-1 protease inhibitor.

For research use only. We do not sell to patients.
Atazanavir sulfate Chemical Structure

Atazanavir sulfate Chemical Structure

CAS No. : 229975-97-7

Size Price Stock Quantity
Free Sample (0.5-1 mg)   Apply now  
10 mM * 1 mL in DMSO USD 79 In-stock
10 mg USD 72 In-stock
50 mg USD 144 In-stock
100 mg USD 240 In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

Other Forms of Atazanavir sulfate:

  • Biological Activity

  • Protocol

  • Technical Information

  • Purity & Documentation

  • References


Atazanavir sulfate is a sulfate salt form of atazanavir that is an highly potent HIV-1 protease inhibitor. Target: HIV-1 protease inhibitor Atazanavir sulfate is a sulfate salt form of atazanavir that is an highly potent HIV-1 protease inhibitor. It has a pharmacokinetic profile that supports once-daily dosing and has demonstrated a unique resistance profile and superior virologic potency compared with other antiretrovirals in vitro. In subjects with HIV, atazanavir (400 mg once daily) produced rapid and sustained improvements in viral load and CD4 counts in both antiretroviral-naive as well as previously treated patients when used in combination with dual nucleoside reverse transcriptase inhibitor (NRTI) treatment [1]. After intravenous (iv), oral (po) and intraportal (ip) administration of ATV at a dosage of 7 mg/kg, AUCs in HL rats were 12.41, 5.24 and 8.89 microg/mLh, respectively, and were significantly higher than those in control rats (4.09, 1.70 and 3.38 microg/mLh). Despite the decrease of distribution volume (Vd(ss)), the terminal half-life (t(1/2)) in HL tended to be shorter than in control, and hepatic distribution of ATV in HL rats was 4.8-fold increases. These results suggested that the uptake of ATV into liver might counteract the decrease of Vd(ss). On the other hand, there was no significant difference in bioavailability, and the lymphatic transport to AUC showed no statistical change. In conclusion, although the protein binding rate and AUC were significantly increased, the pharmacokinetics of ATV might be tolerated in HL [2]. Clinical indications: HIV-1 infection Toxicity: torsades de pointes

Clinical Trial
Preparing Stock Solutions
Concentration Volume Mass 1 mg 5 mg 10 mg
1 mM 1.2454 mL 6.2272 mL 12.4544 mL
5 mM 0.2491 mL 1.2454 mL 2.4909 mL
10 mM 0.1245 mL 0.6227 mL 1.2454 mL
Please refer to the solubility information to select the appropriate solvent.
Molecular Weight







O=C(OC)N[[email protected]@H](C(C)(C)C)C(NN(CC1=CC=C(C2=NC=CC=C2)C=C1)C[[email protected]](O)[[email protected]](CC3=CC=CC=C3)NC([[email protected]](C(C)(C)C)NC(OC)=O)=O)=O.O=S(O)(O)=O

Powder -20°C 3 years
  4°C 2 years
In solvent -80°C 6 months
  -20°C 1 month

Room temperature in continental US; may vary elsewhere

Solvent & Solubility

DMSO; H2O: < 0.1 mg/mL

* "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

Inquiry Online

Your information is safe with us. * Required Fields.

Product name



Applicant name *


Email address *

Phone number *


Organization name *

Country *


Requested quantity *


Bulk Inquiry

Inquiry Information

Product Name:
Atazanavir sulfate
Cat. No.: